Trastuzumab
HER2 Inhibitor
DB00072
Approved Indication
For treatment of early stage HER2-positive breast cancer, or metastatic breast cancer that substantially overexpress HER2.
13
Targets
4
Resistance Mutations
11
References
3D Structure
No structure available
No co-crystal structure available
Protein Targets
Mechanism of Action
Trastuzumab binds to the HER2 (or c-erbB2) proto-oncogene, an EGF receptor-like protein found on 20-30% of breast cancer cells. The binding leads to antibody mediated (complement mediated) killing of the HER2 positive cells.
Resistance Mutations
— 18 resistance samples observed in COSMIC
Click a chip to highlight in viewer
ERBB2
p.L593R
p.L839R
p.L854R
p.L869R
5
Resistance mutations sourced from COSMIC Drug Resistance database. Cyan = on-target · Amber = off-target · numbered badge = PubMed references for that mutation
Details
DrugBank ID
DB00072 ↗
Approval Date
1998-09-25
Molecular Weight
— g/mol
Drug Class
HER2 Inhibitor
ATC Codes
L01XC03
Synonyms
RHUMAB HER2, trastuzumab-dkst
ChEMBL
CHEMBL1201585 ↗
Drug References (DrugBank)